The Catalan pharmaceutical company Grifols achieved a net profit of €227 million in the first half of 2026, a 28.7% increase compared to the previous year. The company maintains its leverage at 4.2 times and confirms its annual targets.
The Sant Cugat del Vallès-based pharmaceutical company, Grifols, has presented semi-annual results that reflect sustained growth. The company closed the first half of 2026 with a net profit of €227 million, representing an increase of 28.7% compared to the same period last year, according to information submitted to the National Securities Market Commission (CNMV).
Total revenues reached €3.574 billion, a 2.8% decrease from the first half of 2025. However, the company highlights that sales were particularly driven by its Biopharma division, which grew by 5.4%. This strategic segment offset declines in other business areas.
Grifols' CEO, Nacho Abia, positively assessed the results: “They reflect the continued strength of our business and the disciplined execution of our strategy.” Abia emphasized that the company remains focused on driving sustainable growth and improving operational efficiency while investing in long-term opportunities.
Meanwhile, the Chief Financial Officer, Rahul Srinivasan, highlighted that the company has continued to strengthen its financial profile. “We have improved the resilience of the balance sheet and reinforced financial flexibility, positioning us strongly to confidently execute our long-term strategic priorities,” he stated.
Among the growth levers that Grifols is managing, the company cites the continued strength of immunoglobulins, the gradual increase of plasma sourced from Egypt, new advances in Biotest recovery, operational leverage from disciplined cost management, and ongoing improvements in free cash flow generation.
On the financial front, Grifols has successfully refinanced all debt maturities due in 2027. The operation included an expanded 'Term Loan B' amounting to approximately €3 billion. Additionally, the company increased the commitment of its revolving credit line from $938 million to over $2 billion, with better pricing terms and longer maturities, supported by strong institutional demand and backing from international financial entities.
The leverage ratio remains at 4.2 times, a level that the company considers manageable and which reinforces investor confidence. For the full year, Grifols confirms its targets, supported by the positive evolution of the business and the efficiency measures implemented.
Internationally, the company continues to develop its strategic alliance with Shanghai RAAS in China, a key market for its expansion. Collaboration with the Chinese partner is one of the avenues to access new markets and sources of plasma, an essential component in the production of blood derivatives.
For the residents of Sant Cugat del Vallès, where Grifols is headquartered, these results represent positive news that reinforces the company's weight in the local economic fabric. The pharmaceutical company is one of the main employers in the Vallès Occidental region, and its evolution directly impacts employment and economic activity in the area.
The company plans to continue investing in R&D and new production capabilities, which could translate into new job opportunities in the coming months. The presentation of the semi-annual results has occurred in a context of stability in financial markets, allowing Grifols to improve its financing conditions and confidently face upcoming debt maturities.
You may also like
